Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction


Grabner M1, Burchard J2, Nguyen C1, Chung H1, Gangan N1, Boniface J2, Zupancic JAF3, Stanek E1
1HealthCore, Inc., Wilmington, DE, USA, 2Sera Prognostics, Salt Lake City, UT, USA, 3Beth Israel Deaconess Medical Center, Boston, MA, USA

Presentation Documents

OBJECTIVES: Preterm birth (PTB) carries increased risk of health problems for infants as well as higher healthcare costs for both infants and mothers. We evaluated the cost-effectiveness of a risk-screening-and-treat strategy, compared to usual care, for a population of commercially-insured pregnant US women without known risk factors for PTB. The strategy included a novel PTB prognostic test (PreTRM®) in the 19th-20th week of pregnancy and treatment with vaginal progesterone and high-intensity case management for the remainder of the pregnancy for women assessed as high-risk.

METHODS: A decision-tree with Markov nodes representing 1-week cycles from week 19 of pregnancy to birth (preterm or full-term) was developed, using a payer’s perspective and time horizon from pregnancy start to 12-months post-delivery in mothers and 30-months from birth in infants. PTB rates and costs were based on real-world cohorts of >40,000 mothers and infants with birth events in 2016, as identified in administrative claims from the HealthCore Integrated Research Database®. Estimates of test performance and treatment effectiveness were derived from published literature. Uncertainty was explored via scenario, one-way, and probabilistic sensitivity analysis (PSA).

RESULTS: In the base-case analysis, the risk-screening-and-treat strategy dominated usual care with 870 fewer PTBs (20% reduction) and $54 million less in total cost ($863 net savings per pregnant woman). Reductions were also seen for neonatal-intensive-care-unit admissions (10%), overall length-of-stay (7%), and births <32 weeks gestation (33%). Treatment effectiveness had the most influence on cost-effectiveness estimates per one-way sensitivity analysis, followed by infant care costs and test costs. The risk-screening-and-treat strategy was dominant in the majority of PSA simulations and model scenarios.

CONCLUSIONS: Use of a novel prognostic test during pregnancy to identify women at risk of PTB combined with evidence-based treatment can reduce total costs and prevent preterm deliveries and their consequences in a representative population of commercially-insured US women.

Conference/Value in Health Info

2021-05, ISPOR 2021, Montreal, Canada

Value in Health, Volume 24, Issue 5, S1 (May 2021)




Economic Evaluation, Epidemiology & Public Health, Medical Technologies: Devices, diagnostics, digital health

Topic Subcategory

Diagnostics & Imaging, Public Health


Pediatrics, Reproductive and Sexual Health

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now